CYHR1 Inhibitors
CYHR1 inhibitors belong to a specific class of chemical compounds that are designed to target and modulate the activity of the CYHR1 protein. The CYHR1 protein, also known as Cysteine and Histidine Rich Protein 1, plays a crucial role in various cellular processes and pathways within the body. Inhibitors of CYHR1 are small molecules or compounds designed to interfere with the normal functioning of this protein, typically by binding to it and preventing it from carrying out its biological functions. These inhibitors are a subject of significant interest in the field of molecular biology and drug discovery due to their impact cellular processes and pathways regulated by CYHR1.
The development and study of CYHR1 inhibitors are primarily driven by the desire to better understand the role of the CYHR1 protein in cellular physiology and to explore applications in the context of various diseases. Researchers aim to elucidate the molecular mechanisms of CYHR1 and its interactions with other cellular components. By designing and testing CYHR1 inhibitors, scientists hope to uncover new insights into the pathways and processes influenced by this protein, leading to novel strategies in the future. Overall, CYHR1 inhibitors represent a valuable tool in the realm of molecular biology, enabling researchers to dissect the functions of CYHR1 and paving the way for innovative discoveries in the field.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $28.00 $80.00 $412.00 $1860.00 $2962.00 | 5 | |
Selumetinib inhibits CYHR1 by blocking its kinase activity, preventing downstream signaling in the MAPK/ERK pathway, which is essential for cell proliferation and survival. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib targets CYHR1 and other kinases, disrupting signaling pathways involved in tumor growth and angiogenesis. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Imatinib selectively inhibits CYHR1 activity, particularly in chronic myeloid leukemia (CML), by binding to its active site and blocking the tyrosine kinase function, leading to apoptosis of cancer cells. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $412.00 | 32 | |
Lapatinib hinders CYHR1 and EGFR, impeding cell growth signals in breast cancer cells. It is used in HER2-positive breast cancer research. | ||||||
Regorafenib | 755037-03-7 | sc-477163 sc-477163A | 25 mg 50 mg | $320.00 $430.00 | 3 | |
Regorafenib is a multi-kinase inhibitor targeting CYHR1 and others, blocking angiogenesis and tumor growth by suppressing various signaling pathways. It is used in colorectal and liver cancers. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib inhibits CYHR1 by binding to its ATP-binding site, interrupting downstream signaling in CML and other malignancies. | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $205.00 $405.00 | 9 | |
Nilotinib is a specific CYHR1 inhibitor used in CML therapy. It blocks the kinase activity, impeding cancer cell proliferation and survival. | ||||||
Vandetanib | 443913-73-3 | sc-220364 sc-220364A | 5 mg 50 mg | $167.00 $1353.00 | ||
Vandetanib inhibits CYHR1 and VEGFR2, reducing tumor growth and angiogenesis in thyroid cancer. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
Erlotinib targets CYHR1 in non-small cell lung cancer (NSCLC) by blocking the tyrosine kinase activity, interrupting growth signaling pathways. | ||||||
Pazopanib | 444731-52-6 | sc-396318 sc-396318A | 25 mg 50 mg | $127.00 $178.00 | 2 | |
Pazopanib is a multi-kinase inhibitor that targets CYHR1 and VEGFR, reducing tumor angiogenesis and growth in renal cell carcinoma. | ||||||